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Background
Acetylcholine (ACh) was viewed as the “vagusstoff” after Loewi`s
experiment with the frog heart [1]. In 1936 Otto Loewi, and Henry
Dale were recipients of the Nobel Prize in Physiology and Medicine,
by their contribution for the acetylcholine discover as a
neurotransmitter [1]. So, ACh was regarded as a neurotransmitter
during several decades [2]. After that it was evidenced a widespread
expression of the cholinergic system within a variety of non-neuronal
tissues. The “Non-Neuronal Cholinergic System” (NNCS) is well
established as the extra-neural effects of acetylcholine [3]. Beyond
these neural and non neuronal cholinergic systems there is another
one named by Tracey et al. as the Cholinergic Anti-Inflammatory
Pathway (CAIP) [4]. Afferent and efferent signals transmitted in the
vagus nerve are components of a neural circuit that modulates the
innate immune response. The CAIP could be considered as a liaison
between the cholinergic neural system and NNCS.
The enzymes implicated in the synthesis and responsible for
hydrolysis of ACh in different mammalian cells are isoenzymes of
Choline-Acetyltransferase (ChAT), and Acetylcholinesterase (AChE)
respectively [5]. ACh is synthesised in the nerve cell from choline and
acetyl-CoA by a process mediated by choline acetyltransferase and is
stored in vesicles in pre-synaptic neurons [2]. Upon arrival of the
nerve impulse, a membrane depolarisation is induced and ACh is
released to the synaptic cleft. At postsynaptic membrane, ACh binds to
its cholinergic receptor, initiating a cascade of actions that are stopped
by the enzyme AChE, which hydrolyses ACh to Choline (Ch) and
acetic acid [2].
Non-Neuronal Cholinergic System (NNCS)
Circulating acetylcholine can be produced by T-lymphocytes and
endothelial cells [6,7].
Lymphocytes express most of the cholinergic elements and upon
interaction with the antigen presenting cells or the endothelial cells, T
cells synthesize and release acetylcholine [8]. The autocrine ACh
action depends on cell membrane receptor and in case of TCR/CD3
receptors for example enhances the expression of both ChAT and M5
mACh receptors [8].
At the vascular wall the ACh produced by the endothelium acts
through the auto-paracrine fashion in the intrinsic intima [5]. All the
neuronal components, ACh, ChAT and VAChT and AChE above
mentioned, are also present in the NNCS [9].
We are the first to perform the biochemical characterization of the
AChE in endothelial cell membrane of human umbilical vein. We have
identified, with C-terminal anti-AChE, the expression of one
molecular form membrane with 70 kDa, (the molecular mass
characteristic of the human monomeric form of AChE). When the N-
terminal anti-AChE was used two molecular forms with
approximately 66 kDa and 77 kDa are expressed at membrane bound
level [10]. The molecular form of 70 kDa is also expressed at cytoplasm
and nuclear compartments, where the latter also expressed an AChE
isoform with approximately 55 kDa [11]. We verified that the nuclear
expression is not endothelial cell-specific but is also evidenced in non-
neuronal and neuronal cells [11].
The widespread expression of non-neuronal acetylcholine is
accompanied by the ubiquitous presence of acetylcholinesterase and
nicotinic/muscarinic receptors. Red blood cells account for the blood
elements with highest expression of membrane-bound
acetylcholinesterase [12]. The enzyme AChE has the particularity to be
inhibited by high concentrations of its own substrate, ACh. So,
different types of enzyme complexes may be presented namely, active,
inactive and less active ones according the amount of ACh existent
[13].
Fuji and co-workers quantified the levels of ACh in plasma and
blood at normal physiological conditions, and verified differences of
its amount among animal species [14].
The circulating ACh induces vasodilation in dependence of
integrity of the endothelium via the Nitric Oxide (NO) synthesised
and released to smooth muscle [15,16]. Also the NO released from
endothelial cells can move to the lumen of the vessels where is
scavenged by erythrocyte and free hemoglobin present in the blood
circulation [17]. The NO-Heme Hemoglobin adduct (HbFe (II) NO)
has been detected during NO inhalation therapy used for pulmonary
hypertension relief, but it also occurs when deoxygenated blood enters
into a vascular bed in which NO is produced such as the pulmonary
circulation [18,19].
Low tissue oxygen tension is perceived by erythrocytes with
induced hemoglobin structural allosteric transitions favouring the
transfer of its NO bound molecule to band 3 that allow the NO efflux
to the tissues in the capillary bed [20,21]. Among the heterotrophic
effectors of oxygen binding hemoglobin, NO binds to the thiol group
of cysteine β93 at high tissue oxygen tension. At low tissue oxygen
tension there is a NO release from either S-nitrosothiol of the S-
nitrosated hemoglobin or from the reduction of the anion nitrite to
NO in a non exclusive way [22,23]. It is known that the T state of
SNO-Hb promotes the transnitrosation by which NO groups are
transferred to thiol acceptors biomolecules in RBCs [24]. One of these
is the protein band 3 [25], but the exact mechanism by which NO
escape from erythrocyte membrane still remain uncertain.
We have verified that in presence of ACh there is an increased of
the erythrocyte deformability, of the nitrite and nitrate concentration
and the oxygen hemoglobin affinity and a decreased of erythrocyte
aggregation [26,27].
The lower erythrocyte deformability expressed in blood samples
obtained from hypertensive, hypercholesterolemic and kidney
Saldanha and Silva-Herdade, Clin Exp Pharmacol 
2014, 4:3
DOI: 10.4172/2161-1459.1000159
Commentary Open Access
Clin Exp Pharmacol
ISSN:2161-1459 CPECR, an open access journal Volume 4 • Issue 3 • 1000159
Journal of
Clinical and Experimental PharmacologyJourna
l o
f C
lin
ica
l & 
Experimental Pharm
acology
ISSN: 2161-1459
transplant patients was ameliorate when in presence of ACh as we
verified by studies conducted in vitro [28].
Non-neuronal acetylcholine appears to be involved in the
regulation of elementary cell functions such as cell mitosis, cell-cell
interaction, cell automaticity, locomotion, ciliary activity, barrier
function, resorption and secretion [29-33]. In the airways, for instance,
the great majority of cells express the components of NNCS and it is
documented that a substantial increase on ACh levels triggers the
release of proinflammatory effectors [34]. In addition, the excitability
of airway mast cells can be powerfully inhibited by acetylcholine [35].
The Cholinergic Anti-Inflammatory Pathway (CAIP)
The vagus nerve innervates major organs, including the spleen and
the gut, regulates physiological responses to stress, injury and
infection. It was observed that the action potential transmitted in
sensory nerve fibers to the brain reports the presence of inflammatory
stimuli in peripheral issues [14].
The electric stimulation of the vagus nerve enhances the release of
acetylcholine from the spleen [36]. Several studies using
immumohistochemistry, electron micrsoscopy and neurophysiological
techniques [37,38] demonstrate communication between the nerve
endings and the T cells, B cells and macrophages that lead to anti-
inflammatory signals through the efferent vagus nerve. Tracey et al.
based on his work proposes the cholinergic anti-inflammatory
pathway [39-41]. It consists in the activation of adrenergic neurons in
the spleen that liberate nor-epinephrine near the T cell capable to
secrete acetylcholine. This pathway plays a critical role in controlling
the inflammatory response through ACh interaction with peripheral
α7 subunit–containing nicotinic acetylcholine receptors expressed on
macrophages which suppress the synthesis and secretion of
inflammatory cytokines. Macrophages act as an interface between the
brain and the immune system [4] by the participation of its JaK2/
STAT3 signal pathway or via inhibition of the transcription factor NF-
kB [42,43]. So, a crosstalk is established between the immune system
and the central nervous system that contribute for the reposition of
homeostasis in the former.
The activation of afferent vagus nerve by endotoxin or pro-
inflammatory cytokines stimulates hypothalamic-pituitary-adrenal
anti-inflammatory responses conducted by the efferent vagus nerve
[44].
Acetylcholine is an anti-inflammatory molecule that suppresses the
production of pro-inflammatory cytokines [3] suggesting that the
neuronal activation of the adrenergic system, for example in spleen,
release nor-epinephrine from the efferent fibers near T cells which
became able to liberate non neuronal acetylcholine. In consequence
this ACh interacts with α7 nAChR expressed on cytokine production
macrophages. The extraneuronal cholinergic system in lymphocytes is
responsible for the levels of acetylcholine in blood circulation [6]. In
the case for example of nicotine application it generates complex
effects in dependence of the route or local of its administration [45,46].
In vivo Experimental Studies of the Effects of ACh in
Inflammatory Response
The study done by Silva-Herdade and Saldanha was conducted in
vivo on an animal model of Lipopolysaccharide (LPS) induced
inflammation aimed to evaluate the effects of ACh on the leukocyte-
endothelial cells interactions and to quantify the concentrations of
TNF-alpha in blood circulation. Using intravital microscopy the
number of rolling and adherent leukocytes in post-capillary venules of
Wistar rats was registered after the intravenously administration of
LPS alone or with further addition of ACh. Those results evidenced
the anti-inflammatory effect of ACh showed by a decrease in TNF-
alpha plasma levels and by the decrease of the number of adherent
leukocytes [47]. Taking in consideration the non neuronal origin of
ACh that we mimesis in these in vivo studies we cannot exclude with
sure the participation of the cholinergic anti-inflammatory pathway
when LPS was administered.
In a previous study the same authors using the same animal model
protocol but without induced inflammation showed decrease of the
number of rolling and adherent leukocytes while the rolling velocity
was reduced without changes in plasma levels of IL-1-beta [48].
We conclude that ACh has an anti inflammatory effect decreasing
the concentration of TNF-alpha in plasma and the adhesion of the
leukocytes to the endothelial cells that is one of the former steps in the
inflammatory innate response. The acute inflammatory state
implicated by the surgery show also the anti-inflammatory action of
ACh that left unchanged IL-1-beta.
Conclusions
Apart from the former discovers of the neuronal action of
acetylcholine much more different cellular locals of synthesis of ACh
are evidenced which implicate diverse biological effects conferring its
ubiquitous molecular behavior. For instance its ubiquity is different
from that of coenzyme Q which moves inside the inner mitochondrial
membrane occupying diverse places closer or away from one complex
of the electron chain but with the same oxi-reduction function.
Acetylcholine acts in the parasympathetic system, in the neuron
muscle junction, in the T-lymphocytes, in endothelial cells, in
erythrocytes demonstrate the ability to bind and be recognized by a
different membrane cell types. ACh induces in the endothelium the
NO synthesis; when within the airway epithelium ACh is involved in
the regulation of water and ion transport; acts as anti inflammatory
agent when liberate by T-cell activation increasing its concentration in
blood circulation. In general terms, the biochemistry point of view that
the structure of one biomolecule dictates its physiological function has
been enlarged by a multitude of actions and effects resulting from the
signal transduction pathway associated with their different kind of
receptors or with the same type of receptors in distinct cells.
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